N1-[4-(3,4-dichlorophenyl)-1,3-thiazol-2yl]-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5-quinazolinyl)acetamide | 1202678-66-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: N1-[4-(3,4-dichlorophenyl)-1,3-thiazol-2yl]-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5-quinazolinyl)acetamide
• 英文别名: N-[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]-2-(1,3-dimethyl-2,4-dioxoquinazolin-5-yl)acetamide
• CAS: 1202678-66-7
• 化学式: C₂₁H₁₆Cl₂N₄O₃S
• 分子量: 475.355
• InChiKey: MESAZEZGAZMOOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS
  申请人：Muthuppalniappan Meyyappan

  公开号：US20090325987A1

  公开（公告）日：2009-12-31

  The present invention provides Quinazolinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

  本发明提供了喹唑啉二酮衍生物作为TRPA（瞬时受体电位亚家族A）调节剂。具体来说，本文描述的化合物可用于治疗或预防由TRPA1（瞬时受体电位亚家族A，成员1）调节的疾病、病况和/或疾病。本文还提供了制备本文描述的化合物的方法、用于合成的中间体、药物组合物以及治疗或预防由TRPA1调节的疾病、病况和/或疾病的方法。
• TREATMENT OF RESPIRATORY DISORDERS USING TRPA1 ANTAGONISTS
  申请人：KHAIRATKAR-JOSHI Neelima

  公开号：US20120316136A1

  公开（公告）日：2012-12-13

  The present patent application relates to treatment of a respiratory disorder using TRPA1 antagonists. Particularly, the present patent application relates to treatment of a respiratory disorder using a TRPA1 antagonist, wherein the TRPA1 antagonist is administered by inhalation route to a subject in need thereof.
• PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID
  申请人：Khairatakar-Joshi Neelima

  公开号：US20140148423A1

  公开（公告）日：2014-05-29

  The present patent application relates to a pharmaceutical composition comprising a transient receptor potential ankyrin-1 receptor (“TRPA1”) antagonist and a glucocorticoid.
• PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND AN ANTICHOLINERGIC AGENT
  申请人：GLENMARK PHARMACEUTICALS S.A.

  公开号：US20140364445A1

  公开（公告）日：2014-12-11

  The present invention relates to a pharmaceutical composition comprising a transient receptor potential ankyrin-1 receptor (“TRPA1”) antagonist and an anticholinergic agent. Particularly, the present invention provides a pharmaceutical composition comprising a TRPA1 antagonist having IC 50 for inhibiting human TRPA1 receptor activity of less than 1 micromolar and an anticholinergic agent; a process for preparing such composition; and its use in treating a respiratory disorder in a subject.
• US7951814B2
  申请人：——

  公开号：US7951814B2

  公开（公告）日：2011-05-31